^
    Back
    Association details:
    Biomarker:KRAS G13A
    Cancer:Non Small Cell Lung Cancer
    Drug:everolimus (mTOR inhibitor) +
    avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.

    Published date:
    05/26/2022
    Excerpt:
    In the KRAS mt NSCLC expansion cohort, 10 patients are evaluable for efficacy and 2 confirmed responses were reported (KRAS mutations G12V and G13A) with an objective response rate (ORR) 20% to date….The median progression free survival (PFS) in the KRAS mt NSCLC cohort is 6.35 months (95% CI 3.52 – not reached)....The combination of VS-6766 with everolimus has shown activity in patients with a variety of KRAS mutation variants including responses in KRAS mt NSCLC.
    DOI:
    10.1200/JCO.2022.40.16_suppl.9018